Edwards Lifesciences vs Intuitive Surgical
EW and ISRG side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EW and ISRG compare
Intuitive Surgical is the larger company, worth 2.9 times as much as Edwards Lifesciences ($153B against $53.0B).
On earnings, Intuitive Surgical is cheaper: it trades at 49.5× trailing earnings, against 52.9× for Edwards Lifesciences.
Intuitive Surgical grew revenue faster over the last twelve months (20.7% versus 14.6% for Edwards Lifesciences).
Intuitive Surgical keeps more of each dollar of sales as profit, with a net margin of 28.4% compared with 15.4% at Edwards Lifesciences.
Intuitive Surgical scores higher on the StockData Score (17 against 10 for Edwards Lifesciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EW | ISRG |
|---|---|---|
| Size and price | ||
| Market cap | $53.0B | $153B |
| Share price | $92.01 | $432.01 |
| Change, 1 year | 11.3% | −19.6% |
| Change, 5 years | −22.5% | 18.4% |
| Beta (5Y) | 1.00 | 1.33 |
| Employees | 16K | 17K |
| StockData Score | ||
| Total score | 10 | 17 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 2 | 4 (better) |
| Performance score | 3 | 5 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 52.9× | 49.5× (better) |
| P/S | 8.1× (better) | 13.8× |
| P/B | 5.0× (better) | 8.4× |
| EV/EBITDA | 30.7× (better) | 42.7× |
| P/FCF | 37.0× (better) | 47.4× |
| PEG | – | 1.70 |
| FCF yield | 2.7% (better) | 2.1% |
| Fair value | $65.85 | $350.05 |
| Margin of safety | −39.7% | −23.4% (better) |
| Growth | ||
| Revenue growth (TTM) | 14.6% | 20.7% (better) |
| Revenue growth, 5Y average | 6.7% | 18.2% (better) |
| Net income growth (TTM) | −75.8% | 20.4% (better) |
| EPS growth (TTM) | −75.0% | 21.8% (better) |
| EPS growth, 5Y average | 7.1% | 21.8% (better) |
| Profitability | ||
| Gross margin | 77.8% (better) | 66.7% |
| Operating margin | 22.3% | 31.3% (better) |
| Net margin | 15.4% | 28.4% (better) |
| FCF margin | 22.0% | 29.2% (better) |
| Return on equity | 9.5% | 17.4% (better) |
| Return on invested capital | 14.3% | 22.5% (better) |
| Financial health | ||
| Debt / equity | 0.06 (better) | 0.00 |
| Net debt / EBITDA | −2.26 | – |
| Current ratio | 4.52 | 4.96 (better) |
| Altman Z-score | 12.90 | 37.48 (better) |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | 2.3% | 2.3% (better) |
| Shareholder yield | 2.3% | 2.3% (better) |
| Ownership | ||
| Held by institutions | 91.0% | 86.9% |
| Held by insiders | 0.22% | 0.47% |
| Insider net buying, 12 months | −$27.7M (better) | −$57.3M |
| Superinvestors holding | 1 | 2 (better) |
| Short interest, % of float | 1.7% | 2.1% |
Go deeper
- EW stock overview
- EW income statement
- EW valuation and score
- ISRG stock overview
- ISRG income statement
- ISRG valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.